We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Metalloproteinases Help Regulate Blood Vessel Formation

By Biotechdaily staff writers
Posted on 22 Apr 2005
Researchers have found that the membrane bound matrix metalloproteinase enzyme (MT1-MMP) contributes to blood vessel formation and is, therefore, an attractive target for chemotherapy through regulation of platelet-derived growth factor-beta (PDGF-beta) signaling.

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases, which are capable of collectively degrading all kinds of extracellular matrix proteins, but also can process a number of bioactive molecules. More...
The MMPs play an important role in tissue remodeling associated with various physiologic and pathologic processes such as morphogenesis, angiogenesis, tissue repair, cirrhosis, arthritis, and tumor invasion.

Investigators at the University of Michigan (Ann Arbor, USA) worked with a strain of genetically engineered mice lacking the gene for MT1-MMP. Results published in the April 15, 2005 issue of Genes & Development revealed that MT1-MMP helped transmit the biochemical signal generated by PDGF-beta to direct mural cell growth in the microvasculature. MT1-MMP-null mice were found to have severely compromised vascular architecture, with irregularly sized vessels and weakened vessel walls.

Senior author Dr. Stephen J. Weiss, professor of internal medicine and oncology at the University of Michigan, said, "These findings, coupled with complementary reports from our group that cancer cells themselves use MT1-MMP to regulate their proliferative and metastatic properties, suggest that therapeutics directed against this single target could prove efficacious in controlling the ability of tumors to recruit new blood vessels, grow, and spread to distant sites.”



Related Links:
University of Michigan

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Multi-Chamber Washer-Disinfector
WD 390
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.